Exploring symptoms and signs of mild thyroid overactivity in Dutch primary care
- Conditions
- Subclinical hyperthyroidismNutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN15496928
- Lead Sponsor
- Amsterdam University Medical Centers
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 200
Cases: Patients with TSH concentration below reference range and with fT4 concentration within reference range (at same measurement) or patients with recorded ICPC code A91.07 (subclinical hyperthyroidism).
Controls: TSH and fT4 measurement within reference range
Cases:
1. In 2 years prior to inclusion use of amiodarone (ATC C01BD01)
2. In 2 years prior to inclusion use of thyroid medication (ATC starting with H03)
3. Ever recorded use of lithium (ATC N05AN01)
4. In 2 years prior to inclusion mention of ICPC T85 (hyperthyroidism), T86 (hypothyroidism), A91.07 (subclinical hyperthyroidism), T71 (thyroid malignancy), A91.06 (subclinical hypothyroidism)
Controls:
During 5-year follow-up from cohort entry date:
1. TSH or FT4 measurement outside of reference range
2. Mention of ICPC codes (see also above) T85, T86, A91.07, T71, A91.06
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiovascular comorbidity and bone health. In the exploratory analyses the exact outcomes will be determined by means of International Classification of Primary Care (ICPC) codes, medication use (such as osteoporosis medication or medication used in heart failure) and relevant laboratory data (for example cholesterol and BNP values), the researchers will compare this comorbidity between the subclinical hyperthyroid group and controls using a dataset over the last 10 years (2012-2022).
- Secondary Outcome Measures
Name Time Method atural course of subclinical hyperthyroidism by TSH and free T4 concentrations using a dataset over the last 10 years (2012-2022)